Literature DB >> 23354995

Gene mutation profiles and prognostic implications in Korean patients with T-lymphoblastic leukemia.

Hee Jae Huh1, Soo Hyun Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Jun Ho Jang, Kihyun Kim, Seok Jin Kim, Won Seog Kim, Chul Won Jung, Ki-O Lee, Sun-Hee Kim, Hee-Jin Kim.   

Abstract

Genetic alterations implicated in the leukemogenesis of T cell acute lymphoblastic leukemia (T-ALL) have been identified in recent years. In this study, we investigated gene mutation profiles and prognostic implications in a series of Korean T-ALL patients. The study patients were 29 Korean patients with T-ALL; 13 adults (45 %) and 16 children (55 %; male-to-female ratio, 25:4). Clinical, hematologic, and cytogenetic findings were reviewed. We performed mutation analyses for NOTCH1, FBXW7, PHF6, and IL7R genes and survival analyses according to the mutational status. Gene mutations were identified in 66 % of the patients in our series (19/29). Eighteen patients (62 %) had NOTCH1/FBXW7 mutations. Sixteen patients (55 %) had NOTCH1 mutations including nine novel mutations, and eight patients (28 %) had known FBXW7 mutations. Eight patients (28 %; six males and two females) had PHF6 mutations including four novel mutations. Three patients (10 %) had IL7R mutations, which were all novel in-frame insertion or deletion-insertions. The gene mutation profile combined with cytogenetics and FISH study for the p16 gene detected genetic aberrations in 90 % of patients (26/29). There was no significant difference in the frequency of gene mutations between the pediatric and adult patients with T-ALL. Survival analyses suggested a favorable prognostic implication of NOTCH1 mutations in adult T-ALL. Gene mutation studies for NOTCH1, FBXW7, PHF6, and IL7R could detect genetic alterations in a majority of Korean T-ALL patients with novel mutations. We observed similar mutation profiles between adult and pediatric T-ALL, and a favorable prognostic implication of NOTCH1 mutations in adult T-ALL.

Entities:  

Mesh:

Year:  2013        PMID: 23354995     DOI: 10.1007/s00277-012-1664-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

Review 1.  The Role of PHF6 in Hematopoiesis and Hematologic Malignancies.

Authors:  Yusra A Eisa; Ying Guo; Feng-Chun Yang
Journal:  Stem Cell Rev Rep       Date:  2022-08-26       Impact factor: 6.692

2.  Structural and functional insights into the human Börjeson-Forssman-Lehmann syndrome-associated protein PHF6.

Authors:  Zhonghua Liu; Fudong Li; Ke Ruan; Jiahai Zhang; Yide Mei; Jihui Wu; Yunyu Shi
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

3.  MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia.

Authors:  Evelien Mets; Gert Van Peer; Joni Van der Meulen; Michael Boice; Tom Taghon; Steven Goossens; Pieter Mestdagh; Yves Benoit; Barbara De Moerloose; Nadine Van Roy; Bruce Poppe; Jo Vandesompele; Hans-Guido Wendel; Pieter Van Vlierberghe; Frank Speleman; Pieter Rondou
Journal:  Haematologica       Date:  2014-06-03       Impact factor: 9.941

Review 4.  PHF6 Degrees of Separation: The Multifaceted Roles of a Chromatin Adaptor Protein.

Authors:  Matthew A M Todd; Danton Ivanochko; David J Picketts
Journal:  Genes (Basel)       Date:  2015-06-19       Impact factor: 4.096

Review 5.  Clinical significance of FBXW7 loss of function in human cancers.

Authors:  Jingyi Fan; Marcia Bellon; Mingyi Ju; Lin Zhao; Minjie Wei; Liwu Fu; Christophe Nicot
Journal:  Mol Cancer       Date:  2022-03-26       Impact factor: 27.401

6.  Meta-analysis of the clinical characteristics and prognostic relevance of NOTCH1 and FBXW7 mutation in T-cell acute lymphoblastic leukemia.

Authors:  Rong-Bin Liu; Jian-Gui Guo; Tian-Ze Liu; Cheng-Cheng Guo; Xin-Xiang Fan; Xiao Zhang; Wei-Han Hu; Xiu-Yu Cai
Journal:  Oncotarget       Date:  2017-06-19

Review 7.  Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

Authors:  Hui Yu; Yuxin Du; Ji Xu; Mingzhi Zhang
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.